Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Phase 2crinecerfontPositive

AI Analysis

Summary

Neurocrine Biosciences initiated a Phase 2 study evaluating crinecerfont in pediatric patients aged 3 months to under 4 years with classic congenital adrenal hyperplasia, assessing safety and tolerability.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.30

Phase_2pediatriccrinecerfontcongenital_adrenal_hyperplasiaclinical_trial_initiation

Related Companies

$NBIX

Read the original article

Published by PR Newswire Pharma on July 1, 2026 8:05 PM

Read Original